NCT05446142 - A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

September 30, 2022

Study Completion Date

September 30, 2022

Conditions

Healthy

Interventions

DRUG

Encorafenib capsule formulation (CAP)

A single encorafenib dose of the CAP formulation

DRUG

Encorafenib first formulation

first formulation

DRUG

Encorafenib second formulation

second formulation

DRUG

Rabeprazole tablet

Proton-pump inhibitor

Trial Locations (1)

New Haven Clinical Research Unit, New Haven